

# Kenji Kita

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4608683/publications.pdf>

Version: 2024-02-01

22  
papers

705  
citations

567281

15  
h-index

752698

20  
g-index

22  
all docs

22  
docs citations

22  
times ranked

1343  
citing authors

#	ARTICLE	IF	CITATIONS
1	Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring <i>EGFR</i> T790M mutation in non-small cell lung cancer cells. <i>Cancer Medicine</i> , 2022, 11, 944-955.	2.8	5
2	FOXO3 is a latent tumor suppressor for FOXO3-positive and cytoplasmic-type gastric cancer cells. <i>Oncogene</i> , 2021, 40, 3072-3086.	5.9	18
3	Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. <i>Nature Communications</i> , 2020, 11, 4607.	12.8	69
4	Glycogen synthase kinase-3 inhibition overcomes epithelial-mesenchymal transition-associated resistance to osimertinib in <i>EGFR</i> mutant lung cancer. <i>Cancer Science</i> , 2020, 111, 2374-2384.	3.9	17
5	Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance. <i>Cancer Science</i> , 2019, 110, 3215-3224.	3.9	32
6	Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2. <i>Oncogene</i> , 2019, 38, 2464-2481.	5.9	75
7	Foretinib Overcomes Entrectinib Resistance Associated with the <i>NTRK1</i> G667C Mutation in <i>NTRK1</i> Fusion-Positive Tumor Cells in a Brain Metastasis Model. <i>Clinical Cancer Research</i> , 2018, 24, 2357-2369.	7.0	25
8	Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer. <i>Carcinogenesis</i> , 2017, 38, 1063-1072.	2.8	16
9	<i>In vivo</i> imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs. <i>Cancer Medicine</i> , 2017, 6, 2972-2983.	2.8	2
10	<i>In vitro</i> and <i>in vivo</i> anti-tumor activity of alectinib in tumor cells with NCOA4-RET. <i>Oncotarget</i> , 2017, 8, 73766-73773.	1.8	10
11	Organ-specific efficacy of HSP90 inhibitor in multiple organ metastasis model of chemorefractory small cell lung cancer. <i>International Journal of Cancer</i> , 2016, 138, 1281-1289.	5.1	14
12	Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression. <i>Oncogene</i> , 2016, 35, 3587-3597.	5.9	30
13	Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma. <i>Cancer Science</i> , 2015, 106, 102-107.	3.9	9
14	<i>In vivo</i> imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line. <i>Cancer Science</i> , 2015, 106, 244-252.	3.9	32
15	Abstract 5122: In vivo imaging models of bone and brain metastases and pleural carcinomatosis developed using a novel human EML4-ALK lung cancer cell line, A925LPE3. , 2015, , .		0
16	Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. <i>Oncotarget</i> , 2014, 5, 4920-4928.	1.8	46
17	Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in <i>EGFR</i>-Mutant Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2149-2157.	4.1	81
18	Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells. <i>Clinical Cancer Research</i> , 2012, 18, 3592-3602.	7.0	104

#	ARTICLE	IF	CITATIONS
19	Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1078-1085.	1.1	34
20	Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-Induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer. <i>American Journal of Pathology</i> , 2012, 181, 1034-1043.	3.8	55
21	Abstract B21: E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells. <i>Clinical Cancer Research</i> , 2012, 18, B21-B21.	7.0	0
22	Genetically engineered humanized anti-Ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small cell lung cancer cells. <i>Cancer Science</i> , 2011, 102, 2157-2163.	3.9	31